Pharnext to Present at the H.C. Wainwright Annual Global Life Sciences Conference
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA) , a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced that company management will present a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference .
The presentation will take place as follows:
- Date: Tuesday, April 10th , 2018
- Time: 2:10 pm CEST
- Venue: Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco
Pharnext’s first-in-class PLEODRUG™, PXT3003, is currently in an international Phase 3 trial for the treatment of the rare disease Charcot-Marie-Tooth disease type 1A. The results of this trial are expected before the end of 2018.
If you are interested in meeting the Pharnext management team during this event or if you need more information about Pharnext's participation, please send an email to firstname.lastname@example.org
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
For more information, visit www.pharnext.com .
Xavier Paoli, +33 (0)1 41 09 22 30
Chief Commercial Officer
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Media Relations (Europe)
Caroline Carmagnol / Aurore Gangloff
+33 (0)1 44 54 36 64
Media Relations (U.S.)
Marion Janic, +1 212 223 4017
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skriv dig op her og modtag pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
EGON-ZEHNDER/MOBIUS20.9.2018 08:03 | pressemeddelelse
Egon Zehnder and Mobius Executive Leadership Formalize Exclusive Strategic Partnership
TWISPAY20.9.2018 08:02 | pressemeddelelse
Twispay Teams up with Blue Air to Expand Digital Payments
ALIBABA-GROUP20.9.2018 06:02 | pressemeddelelse
Alibaba A.I. Labs Launches Hospitality Robot
CELLTRION20.9.2018 04:05 | pressemeddelelse
Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis
NV-RIMINI-STREET,-INC.20.9.2018 01:02 | pressemeddelelse
Rimini Street Obtains Australian Single Touch Payroll Certification
CT-BATTEA-GLOBAL-LITIGAT20.9.2018 00:36 | pressemeddelelse
Litigation Researchers Believe - Dutch Court Ruling - Big Blow to Petrobras’ Arbitration Strategy
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum